Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashwathi Puravankara Menon

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Molecular Therapy. Nucleic Acids|August 22, 2022
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progressionDaniel Meraviglia-Crivelli, Helena Villanueva, Ashwathi Puravankara Menon, et al.
Molecular Therapy. Nucleic Acids|June 26, 2020
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?Mayte Sola, Ashwathi Puravankara Menon, Beatriz Moreno, et al.
Cancers|February 25, 2023
Modulating T Cell Responses by Targeting CD3Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2019
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor ImmunityMario Martínez Soldevilla, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Molecular Cancer|November 29, 2022
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 inductionDaniel Meraviglia-Crivelli, Helena Villanueva, Angelina Zheleva, et al.
Molecular Therapy. Nucleic Acids|May 15, 2024
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancerAshwathi Puravankara Menon, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Molecular Therapy. Nucleic Acids|August 22, 2022
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progressionDaniel Meraviglia-Crivelli, Helena Villanueva, Ashwathi Puravankara Menon, et al.
Molecular Therapy. Nucleic Acids|June 26, 2020
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?Mayte Sola, Ashwathi Puravankara Menon, Beatriz Moreno, et al.
Cancers|February 25, 2023
Modulating T Cell Responses by Targeting CD3Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2019
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor ImmunityMario Martínez Soldevilla, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Molecular Cancer|November 29, 2022
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 inductionDaniel Meraviglia-Crivelli, Helena Villanueva, Angelina Zheleva, et al.
Molecular Therapy. Nucleic Acids|May 15, 2024
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancerAshwathi Puravankara Menon, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Pageof 1